FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594169910> ?p ?o ?g. }

• W2594169910 endingPage "791" @default.
• W2594169910 startingPage "791" @default.
• W2594169910 abstract "Uncertainty exists regarding potential survival benefits of bivalirudin compared with heparin with routine or optional use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-segment elevation myocardial infarction (STEMI). Few data are available regarding long-term mortality in the context of contemporary practice with frequent use of radial access and novel platelet adenosine diphosphate P2Y12 receptor inhibitors.To assess the effect of bivalirudin monotherapy compared with unfractionated or low-molecular-weight heparin plus optional GPIs on 1-year mortality.This international, randomized, open-label clinical trial (EUROMAX [European Ambulance Acute Coronary Syndrome Angiography]) included 2198 patients with STEMI undergoing transport for primary percutaneous coronary intervention from March 10, 2010, through June 20, 2013, and followed up for 1 year. Patients were randomized (1:1) in ambulance to bivalirudin monotherapy vs unfractionated or low-molecular-weight heparin plus optional GPIs (control group). Analysis was based on intention to treat.The primary outcome of this prespecified analysis was 1-year mortality. All deaths were adjudicated as cardiac or noncardiac by an independent, blinded clinical events committee. One-year mortality was assessed and examined across multiple prespecified subgroups.Of the 2198 patients enrolled (1675 men [76.2%] and 523 women [23.8%]; median [interquartile range] age, 62 [52-72] years), complete 1-year follow-up data were available for 2164 (98.5%). All-cause 1-year mortality occurred in 118 patients (5.4%). The number of all-cause deaths was the same for both treatment groups (59 deaths; relative risk [RR], 1.02; 95% CI, 0.72-1.45; P = .92). No differences were noted in the rates of 1-year cardiac death (44 [4.0%] for the bivalirudin group vs 48 [4.3%] for the control group; RR, 0.93; 95% CI, 0.63-1.39; P = .74) or noncardiac death (15 [1.4%] for the bivalirudin group vs 11 [1.0%] for the control group; RR, 1.39; 95% CI, 0.64-3.01; P = .40). Results were consistent across the prespecified patient subgroups. The rate of deaths occurring from 30 days to 1 year was also similar (27 [2.5%] in the bivalirudin group vs 25 [2.3%] in the control group; RR, 1.10; 95% CI, 0.64-1.88; P = .73).In patients with STEMI who were being transported for primary percutaneous coronary intervention, treatment with bivalirudin or with heparin with optional use of GPI resulted in similar 1-year mortality. The reduced composite end point of death and/or major bleeding at 30 days in the bivalirudin arm of the EUROMAX trial did not translate into reduced cardiovascular or all-cause death at 1 year.clinicaltrials.gov Identifier: NCT01087723." @default.
• W2594169910 created "2017-03-16" @default.
• W2594169910 creator A5003345910 @default.
• W2594169910 creator A5003831287 @default.
• W2594169910 creator A5007123733 @default.
• W2594169910 creator A5021517783 @default.
• W2594169910 creator A5022860068 @default.
• W2594169910 creator A5045650183 @default.
• W2594169910 creator A5049568124 @default.
• W2594169910 creator A5065347832 @default.
• W2594169910 creator A5075273346 @default.
• W2594169910 creator A5077305881 @default.
• W2594169910 creator A5079147407 @default.
• W2594169910 creator A5085798844 @default.
• W2594169910 date "2017-07-01" @default.
• W2594169910 modified "2023-10-17" @default.
• W2594169910 title "One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction" @default.
• W2594169910 cites W1278248171 @default.
• W2594169910 cites W1551289483 @default.
• W2594169910 cites W1766979050 @default.
• W2594169910 cites W187729563 @default.
• W2594169910 cites W1957635101 @default.
• W2594169910 cites W2016463307 @default.
• W2594169910 cites W2036761319 @default.
• W2594169910 cites W2103428481 @default.
• W2594169910 cites W2114758846 @default.
• W2594169910 cites W2142825093 @default.
• W2594169910 cites W2149933092 @default.
• W2594169910 cites W2164624937 @default.
• W2594169910 cites W2290592739 @default.
• W2594169910 cites W2359335190 @default.
• W2594169910 cites W80146237 @default.
• W2594169910 doi "https://doi.org/10.1001/jamacardio.2016.5975" @default.
• W2594169910 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5543319" @default.
• W2594169910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28273285" @default.
• W2594169910 hasPublicationYear "2017" @default.
• W2594169910 type Work @default.
• W2594169910 sameAs 2594169910 @default.
• W2594169910 citedByCount "16" @default.
• W2594169910 countsByYear W25941699102017 @default.
• W2594169910 countsByYear W25941699102018 @default.
• W2594169910 countsByYear W25941699102019 @default.
• W2594169910 countsByYear W25941699102020 @default.
• W2594169910 countsByYear W25941699102021 @default.
• W2594169910 countsByYear W25941699102022 @default.
• W2594169910 countsByYear W25941699102023 @default.
• W2594169910 crossrefType "journal-article" @default.
• W2594169910 hasAuthorship W2594169910A5003345910 @default.
• W2594169910 hasAuthorship W2594169910A5003831287 @default.
• W2594169910 hasAuthorship W2594169910A5007123733 @default.
• W2594169910 hasAuthorship W2594169910A5021517783 @default.
• W2594169910 hasAuthorship W2594169910A5022860068 @default.
• W2594169910 hasAuthorship W2594169910A5045650183 @default.
• W2594169910 hasAuthorship W2594169910A5049568124 @default.
• W2594169910 hasAuthorship W2594169910A5065347832 @default.
• W2594169910 hasAuthorship W2594169910A5075273346 @default.
• W2594169910 hasAuthorship W2594169910A5077305881 @default.
• W2594169910 hasAuthorship W2594169910A5079147407 @default.
• W2594169910 hasAuthorship W2594169910A5085798844 @default.
• W2594169910 hasBestOaLocation W25941699101 @default.
• W2594169910 hasConcept C119060515 @default.
• W2594169910 hasConcept C126322002 @default.
• W2594169910 hasConcept C151730666 @default.
• W2594169910 hasConcept C164705383 @default.
• W2594169910 hasConcept C2777565915 @default.
• W2594169910 hasConcept C2779343474 @default.
• W2594169910 hasConcept C2780400711 @default.
• W2594169910 hasConcept C500558357 @default.
• W2594169910 hasConcept C71924100 @default.
• W2594169910 hasConcept C86803240 @default.
• W2594169910 hasConceptScore W2594169910C119060515 @default.
• W2594169910 hasConceptScore W2594169910C126322002 @default.
• W2594169910 hasConceptScore W2594169910C151730666 @default.
• W2594169910 hasConceptScore W2594169910C164705383 @default.
• W2594169910 hasConceptScore W2594169910C2777565915 @default.
• W2594169910 hasConceptScore W2594169910C2779343474 @default.
• W2594169910 hasConceptScore W2594169910C2780400711 @default.
• W2594169910 hasConceptScore W2594169910C500558357 @default.
• W2594169910 hasConceptScore W2594169910C71924100 @default.
• W2594169910 hasConceptScore W2594169910C86803240 @default.
• W2594169910 hasIssue "7" @default.
• W2594169910 hasLocation W25941699101 @default.
• W2594169910 hasLocation W25941699102 @default.
• W2594169910 hasLocation W25941699103 @default.
• W2594169910 hasLocation W25941699104 @default.
• W2594169910 hasLocation W25941699105 @default.
• W2594169910 hasOpenAccess W2594169910 @default.
• W2594169910 hasPrimaryLocation W25941699101 @default.
• W2594169910 hasRelatedWork W2019558585 @default.
• W2594169910 hasRelatedWork W2101065585 @default.
• W2594169910 hasRelatedWork W2355614377 @default.
• W2594169910 hasRelatedWork W2375584960 @default.
• W2594169910 hasRelatedWork W2782203991 @default.
• W2594169910 hasRelatedWork W2895827445 @default.
• W2594169910 hasRelatedWork W2918435398 @default.
• W2594169910 hasRelatedWork W2943113283 @default.
• W2594169910 hasRelatedWork W3029448752 @default.
• W2594169910 hasRelatedWork W3123872059 @default.

• next